Literature DB >> 15217554

Stem cell transplantation for multiple myeloma: current status and future directions.

Humberto Caldera1, Sergio Giralt.   

Abstract

High-dose chemotherapy or chemoradiation therapy supported with autologous stem cell transplantation is now recognized as a valid therapeutic option for patients with multiple myeloma. Results of randomized trials have established autografting as the treatment of choice for patients younger than 65 years, as part of their initial therapy. In this review, the issues of who benefits from transplant, what is the optimal procedure, and whether there is a potential role for allografting are addressed.

Entities:  

Mesh:

Year:  2004        PMID: 15217554

Source DB:  PubMed          Journal:  Curr Hematol Rep        ISSN: 1540-3408


  2 in total

1.  Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells.

Authors:  In-Sung Song; Yu Jeong Jeong; Seung Hun Jeong; Hye Jin Heo; Hyoung Kyu Kim; Sung Ryul Lee; Tae Hee Ko; Jae Boum Youm; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Jin Han
Journal:  Exp Mol Med       Date:  2013-10-25       Impact factor: 8.718

2.  Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.

Authors:  Irfan Kuku; Mehmet Refik Bayraktar; Emin Kaya; Mehmet Ali Erkurt; Nihayet Bayraktar; Kerim Cikim; Ismet Aydogdu
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.